Key Stats for Hims & Hers Stock
- Current Price: $28.27
- J.P. Morgan Target: $35 (December 2026)
- Street Mean Target: ~$26
- TIKR Mid-Case Target: ~$53
- Potential Total Return (TIKR Mid): ~89%
- Annualized IRR: ~15% / year
- Q4 2025 Earnings Reaction: (0.32%) February 23, 2026
- Max Drawdown: 78.06% February 27, 2026
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Sentiment around Hims & Hers Health (HIMS) has never been more split. The stock crashed 78% from its 52-week high of $70.43 to a low of $13.74 after an FDA warning letter, a Novo Nordisk patent lawsuit, and a DOJ referral landed within two weeks of each other in February. Then it rallied more than 30% over the past month.
Bulls argue the March Novo Nordisk settlement removed the existential legal threat and that the platform’s expansion into testosterone therapy, menopause care, diagnostics, and international markets makes GLP-1 a chapter in the story, not the whole book. Bears say the transition from high-margin compounded products to lower-margin branded Wegovy will compress earnings well into 2026, with consensus forecasting an ~80% decline in adjusted EPS for Q1 even as revenue grows modestly.
The unresolved question: is this a company in a managed transition, or one that permanently lost its most profitable growth engine? J.P. Morgan answered on April 24 with an Overweight rating and a $35 price target, arguing the current valuation underestimates the platform’s long-term potential.
Why J.P. Morgan Sees the Selloff as Overdone
J.P. Morgan initiated coverage on April 24, 2026, with an Overweight rating and a $35 December 2026 price target, highlighting a promising catalyst path, particularly Hims’ recent collaboration with Novo Nordisk. The firm also noted that easing FDA restrictions on certain peptides could significantly broaden Hims’ market opportunities.
Shares surged nearly 10% on the initiation day. The Street as a whole, though, remains cautious. Per TIKR data as of May 8, the analyst breakdown is 1 Buy, 3 Outperform, 12 Hold, 1 Underperform, and 1 Sell, with a mean price target of around $26. The stock at $28.27 is already trading above that consensus, meaning most of Wall Street has not yet confirmed J.P. Morgan’s view.
See historical and forward estimates for Hims & Hers stock (It’s free!) >>>
The Transition: Real Cost, Real Progress
The weight-loss pivot was painful. In February, Novo Nordisk sued Hims after the company launched a $49 compounded semaglutide pill. The FDA pledged decisive enforcement steps, and Hims pulled the product within days. By March 9, the two companies settled: Hims would offer Novo’s branded GLP-1 medications at the same prices as other telehealth platforms and stop advertising compounded GLP-1 products.
The settlement ended the legal crisis but not the margin pressure. TIKR consensus puts FY2026 revenue at around $2.72 billion, up just 16% from $2.35 billion in 2025, compared to 59% growth the year prior. FY2026 EBITDA is expected to be around $329 million, essentially flat against $318 million in 2025, as the branded product shift absorbs most of the platform’s operating leverage.
But that number misses what CFO Yemi Okupe explained at the Morgan Stanley Technology, Media & Telecom Conference on March 2. Hims launched three complicated new specialties: low testosterone, menopausal support, and diagnostics, in six months in late 2025. “That is a testament to the investment in the engineering and technology teams,” Okupe said. The Hers brand is tracking toward $1 billion in annual revenue in 2026, growing triple digits year over year as of the most recent quarter, entirely separate from the GLP-1 transition.
Okupe also reaffirmed management’s 2030 targets: $6.5 billion in revenue and $1.3 billion in EBITDA. Whether those are achievable depends on how fast new specialties and international markets scale.
The International Bet
In February, Hims announced a $1.15 billion agreement to acquire Eucalyptus, a digital health leader operating across Australia, the UK, Germany, Japan, and Canada, expected to close mid-2026. Eucalyptus carries annualized recurring revenue north of $450 million.
Okupe framed the logic clearly at the Morgan Stanley conference: the domestic business was not EBITDA-profitable until the end of 2023, reached net income profitability in 2024, and generated $300 million in operating cash flow by 2025. “These things tend to compound pretty quickly,” he said, projecting international revenue reaching at least $1 billion within a few years. Today, the international segment contributed $133.99 million in FY2025 revenue against $2.21 billion from the U.S., under 6% of total. For investors who believe Eucalyptus tracks the domestic arc, that ratio is where much of the long-term upside is hidden.
See how Him & Hers performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $28.27
- TIKR Mid-Case Target: ~$53
- Potential Total Return: ~89%
- Annualized IRR: ~15% / year
See analysts’ growth forecasts and price targets for Hims & Hers stock (It’s free!) >>>
The mid-case assumes a revenue CAGR of around 12% and net income margins expanding toward 9%. The two primary revenue drivers are new specialty growth (testosterone, menopause, diagnostics, longevity) and international expansion via Eucalyptus. The margin engine is operating leverage on Hims’ built-out infrastructure: TIKR consensus shows EBITDA margins expanding from around 12% in 2026 toward 17% by 2030, while free cash flow is forecast to grow from $57 million in FY2025 to around $443 million by 2030.
The upside case is a new specialties scale to Okupe’s stated $100M-plus run rates quickly and international hits $1 billion on the domestic timeline. The downside is the GLP-1 margin drag extends beyond 2026, Eucalyptus integration disappoints, and new specialties fail to fill the gap. Net debt of $543 million at 2.87x LTM EBITDA leaves some balance sheet sensitivity if the transition runs long. The TIKR model entry price is $28.27 as of May 8, 2026.
Conclusion
When Hims & Hers reports Q1 2026 results on May 11, the single metric to watch is GLP-1 subscriber attrition. If users are transitioning from compounded to branded Wegovy at the low end of management’s guided range, the platform’s retention mechanics are intact. If attrition runs worse, it raises the core bear case: that the compounded product was the subscriber driver, not the Hims brand. The thesis in one line, Hims & Hers is a platform company in mid-pivot, not a GLP-1 company in retreat, is exactly what J.P. Morgan’s Overweight is betting on.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Hims & Hers?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Hims & Hers, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Hims & Hers alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Hims & Hers on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
